NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $333.85 -2.82 (-0.84%) Closing price 09/21/2026 04:00 PM EasternExtended Trading$334.50 +0.65 (+0.19%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Krystal Biotech Stock (NASDAQ:KRYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$332.44▼$341.1550-Day Range$312.57▼$371.4752-Week Range$158.08▼$382.54Volume210,258 shsAverage Volume261,706 shsMarket Capitalization$9.88 billionP/E Ratio41.84Dividend YieldN/APrice Target$365.80Consensus RatingModerate Buy Company Overview Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas. Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering. Vyjuvek was approved by the U.S. Food and Drug Administration in 2023 and is marketed in the United States. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech is also developing additional gene therapy candidates for rare dermatological, pulmonary and other genetic diseases. Its pipeline has included programs such as KB407 for cystic fibrosis and KB408 for alpha-1 antitrypsin deficiency. The company is led by President and Chief Executive Officer Krish S. Krishnan, who co-founded Krystal Biotech with Suma Krishnan.AI Generated. May Contain Errors. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 71% of companies evaluated by MarketBeat, and ranked 230th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingKrystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Krystal Biotech is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKrystal Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth24.73% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 24.73% in the coming year, from $7.48 to $9.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 41.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 41.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.10.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 7.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.02% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 15.27, which indicates bearish sentiment.Change versus previous monthShort interest in Krystal Biotech has recently increased by 4.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. News and Social Media4.7 / 5News Sentiment1.47 News SentimentKrystal Biotech has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 5 articles on an average week.Search Interest5 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows8 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,558,270.00 in company stock.Percentage Held by Insiders13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesBofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy RatingSeptember 21 at 11:55 PM | marketscreener.comMSuma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) StockSeptember 5, 2026 | insidertrades.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 22 at 1:00 AM | Paradigm Press (Ad)Krystal Biotech to Participate in 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | quiverquant.comQKrystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comKrystal Biotech (KRYS) Has a New Rating from RBC CapitalAugust 17, 2026 | theglobeandmail.comHere are Friday’s top Wall Street analyst research calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, SanDisk, T-Mobile US, Wayfair, and ...August 14, 2026 | msn.comKrystal Biotech (KRYS) Q2 2026 Earnings Call TranscriptAugust 10, 2026 | finance.yahoo.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $246.54 at the beginning of 2026. Since then, KRYS stock has increased by 35.4% and is now trading at $333.85. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings results on Monday, August, 3rd. The company reported $1.79 EPS for the quarter, topping analysts' consensus estimates of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a trailing twelve-month return on equity of 19.34%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $40 million in an IPO on Wednesday, September 20th 2017. The company issued 3,960,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Top institutional investors of Krystal Biotech include BlackRock Inc. (14.13%), William Blair Investment Management LLC (1.93%), Jupiter Topco LLC (0.87%) and Bank of America Corp DE (0.87%). Insiders that own company stock include Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, John Charles Thomas and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/03/2026Today9/22/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KRYS's financial health is in the Green zone, according to TradeSmith. KRYS has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees295Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$365.80 High Price Target$474.00 Low Price Target$284.00 Potential Upside/Downside+9.6%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$7.98 Trailing P/E Ratio41.84 Forward P/E Ratio44.63 P/E GrowthN/ANet Income$204.83 million Net Margins54.82% Pretax Margin51.45% Return on Equity19.34% Return on Assets17.65% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio7.96 Sales & Book Value Annual Sales$389.13 million Price / Sales25.40 Cash Flow$7.23 per share Price / Cash Flow46.19 Book Value$42.06 per share Price / Book7.94Miscellaneous Outstanding Shares29,600,000Free Float25,722,000Market Cap$9.88 billion OptionableOptionable Beta0.54 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:KRYS) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...Trading Wire | Sponsored10% yields… from a gold security?Most stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the wor...Golden Portfolio | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
